Drug Profile
Research programme: cannabinoids diagnostics and therapeutics - CellPoint/Vyripharm Biopharmaceuticals
Alternative Names: 68Ga-N4-Endocannabinoid; 99mTc EC-OS2-DZ; 99mTc-N4-Endocannabinoid; 99mTc-N4-Tryptophan; 99mTc-N4-Tyrosine; EC-OS-Methotrexate; N4-EndocannabinoidLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator CellPoint; Vyripharm Biopharmaceutical
- Class Antiepileptic drugs; Cannabinoids; Diagnostic conjugates
- Mechanism of Action Cannabinoid receptor agonists; Dopamine receptor agonists; Serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy; Neurological disorders; Post-traumatic stress disorders
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Epilepsy in USA (Transdermal, Patch)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Neurological-disorders(Diagnosis) in USA
- 28 Aug 2021 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (Transdermal, Patch)